Silodosin in the treatment of benign prostatic hyperplasia.

Article Details

Citation

Copy to clipboard

Rossi M, Roumeguere T

Silodosin in the treatment of benign prostatic hyperplasia.

Drug Des Devel Ther. 2010 Oct 27;4:291-7. doi: 10.2147/DDDT.S10428.

PubMed ID

21116335 [ View in PubMed

]

Abstract

Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents have been shown to prevent symptomatic progression of the disease. The aim of this article is to offer a critical review of the current literature on silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity for alpha(1A)-adrenergic receptors, as compared with both alpha(1B)- and alpha(1D) -adrenoceptors, exceeding the selectivity of all currently used alpha(1)-blockers, and with clinically promising effects.

DrugBank Data that Cites this Article

Drugs

Silodosin

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Silodosin Posaconazole	The metabolism of Silodosin can be decreased when combined with Posaconazole.
Silodosin Ergotamine	The metabolism of Silodosin can be decreased when combined with Ergotamine.
Silodosin Nefazodone	The metabolism of Silodosin can be decreased when combined with Nefazodone.
Silodosin Darunavir	The metabolism of Silodosin can be decreased when combined with Darunavir.
Silodosin Nelfinavir	The metabolism of Silodosin can be decreased when combined with Nelfinavir.